Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142909 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT00142909 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 86 participants.
The verdict
NCT00142909, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
Lofexidine is an experimental medication that may be beneficial in reducing opiate withdrawal symptoms, such as sleep difficulty, anxiety, and tension. The purpose of this study is to determine whether lofexidine in combination with naltrexone can improve an individual's ability to cope with stress and subsequently increase the chances of remaining abstinent from opiates.
Interventions
- DRUG Placebo
- DRUG Lofexidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2005-02 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142909
The ClinicalTrials.gov registry entry for NCT00142909 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00142909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142909 about?
NCT00142909 is a clinical study titled "Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1". Lofexidine is an experimental medication that may be beneficial in reducing opiate withdrawal symptoms, such as sleep difficulty, anxiety, and tension. The purpose of this study is to determine whether lofexidine in combination with naltrexone can improve an individual's ability to cope with stress ...
What is the current status of trial NCT00142909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2005-02. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00142909?
The interventions under investigation include: Placebo (DRUG), Lofexidine (DRUG).
Who is sponsoring clinical trial NCT00142909?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.